middle.news
Actinogen Extends Cash Runway After Positive XanaMIA Interim Analysis
9:32am on Wednesday 29th of April, 2026 AEST
•
Biotechnology
Read Story
Actinogen Extends Cash Runway After Positive XanaMIA Interim Analysis
9:32am on Wednesday 29th of April, 2026 AEST
Key Points
Positive interim analysis supports XanaMIA trial continuation
Open-label extension phase launched with strong participant uptake
$16.8 million capital raising completed to fund operations
Cash position extended beyond expected November 2026 topline results
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Actinogen Medical (ASX:ACW)
OPEN ARTICLE